• Episode 1: Hear Davida Kruger, NP and Julio Rosenstock, MD discuss important head-to-head data between a GLP-1 RA and DPP-4 inhibitor as an important consideration when making clinical decisions for patients with T2D.

  • Mar 27 2023
  • Duración: 17 m
  • Podcast

Episode 1: Hear Davida Kruger, NP and Julio Rosenstock, MD discuss important head-to-head data between a GLP-1 RA and DPP-4 inhibitor as an important consideration when making clinical decisions for patients with T2D.

  • Resumen

  • Episode 1: Hear Davida Kruger, NP and Julio Rosenstock, MD discuss important head-to-head data between a GLP-1 RA and DPP-4 inhibitor as an important consideration when making clinical decisions for patients with T2D.

    This podcast is sponsored by Novo Nordisk, Inc. and is intended for clinicians.

    Más Menos

Lo que los oyentes dicen sobre Episode 1: Hear Davida Kruger, NP and Julio Rosenstock, MD discuss important head-to-head data between a GLP-1 RA and DPP-4 inhibitor as an important consideration when making clinical decisions for patients with T2D.

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.